Loading...
XNAS
BGMSP
Market cap2mUSD
Dec 05, Last price  
4.17USD
1D
11.20%
1Q
-13.13%
Jan 2017
-32.74%
Name

Cyclacel Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:BGMSP chart
P/E
—
P/S
161.63
EPS
—
Div Yield, %
3.60%
Shrs. gr., 5y
173.37%
Rev. gr., 5y
22.87%
Revenues
43k
-89.76%
813,000387,000129,000877,000911,000686,000699,00069,0001,084,0001,734,0001,944,000843,0000150,0000000420,00043,000
Net income
-11m
L-50.29%
-29,416,000-29,258,000-24,053,000-40,386,000-19,570,000-16,021,000-15,243,000-13,186,000-10,153,000-19,387,000-14,342,000-11,791,000-7,470,000-7,288,000-7,828,000-8,445,000-18,887,000-21,198,000-22,555,000-11,212,000
CFO
-8m
L-50.41%
-21,510,000-20,172,000-23,140,000-29,905,000-15,193,000-16,044,000-13,977,000-12,043,000-18,199,000-18,702,000-14,460,000-10,079,000-7,480,000-6,701,000-9,447,000-7,934,000-18,540,000-20,827,000-16,111,999-7,990,000
Dividend
Jan 19, 20240.15 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
URL
https://cyclacel.com/
IPO date
Jan 01, 1996
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT